CLINICAL POLICIES AND PROTOCOLS

Bureau of Tuberculosis Control
New York City Department of Health and Mental Hygiene
## Table of Contents

### Section III. Treatment of Pulmonary Tuberculosis

**Regimens for Treatment of Drug-Susceptible Tuberculosis** ........................................ 43
- Standard regimen ........................................ 43
- Length of treatment ...................................... 43

**Intermittent Regimens** ........................................ 44

**Rifapentine** .......................................................... 46
- Patient selection ............................................ 46
- Treatment length ......................................... 48
- Dosing ......................................................... 48
- Monitoring .................................................. 48
- Adverse reactions ........................................ 48
- Use in pregnant and breast-feeding women ..... 48
- Use in children ............................................. 48
- Drug interactions ........................................ 48

**Treatment of Co-existent Tuberculosis and HIV** ........................................ 49
- Antiretroviral drugs and rifamycins ..................... 49
- Treatment options ......................................... 52
- General considerations .................................. 52
- Immune reconstitution inflammatory syndrome .... 56

**Regimens for Pregnant Women** ........................................ 56
- Standard regimen for pregnant women............... 57
- Length of treatment ...................................... 57
- Regimen for pregnant women suspected or known to have tuberculosis resistant to isoniazid and rifampin (MDRTB) ................................................................. 58
- Anti-tuberculosis medications in breast-feeding women .................................................. 58

**Regimens for Children** ............................................ 59
- Standard regimen ........................................... 59
- Length of treatment regardless of culture results .... 60
- Adverse events in children ............................... 60

**Regimens for Patients with Chronic Renal Failure** ........................................ 60

**Regimens for Patients with Liver Disease** ........................................ 61

**The Use of Pyridoxine (Vitamin B₆) in Tuberculosis Treatment** ........................................ 62

**Anti-Tuberculosis Drugs and Meals** ........................................ 62

**Directly Observed Therapy** ........................................ 63
- Protocol for providing directly observed therapy ... 63
- Priority of patients for directly observed therapy .... 64

**Determination of Treatment Completion** ........................................ 64
- Interrupted or incomplete treatment .................. 65
- Renewal of tuberculosis treatment ................... 65
- Continuation of lapsed treatment ..................... 65
- Protocols for reinstituting treatment ................. 65
- Treatment failure .......................................... 67
- Treatment of coexistent tuberculosis and disseminated *Mycobacterium avium-intracellulare* ........................................ 67

**Key Sources** ............................................................. 68

### Section IV. Evaluation and Treatment of Extrapulmonary Tuberculosis

**Lymphatic Tuberculosis** ........................................ 72
- Diagnosis ................................................... 72
- Treatment ................................................... 72

**Pleural Tuberculosis** ............................................ 72
- Diagnosis ................................................... 73
- Treatment ................................................... 73

**Pericardial Tuberculosis** ........................................ 73
- Diagnosis ................................................... 73
- Treatment ................................................... 73
# Table of Contents

**Central Nervous System Tuberculosis** .................73
  - Diagnosis of meningeal tuberculosis ...........73
  - Treatment of meningeal tuberculosis ..........74
  - Tuberculoma ..............................................75

**Disseminated Tuberculosis** ............................75
  - Diagnosis ..................................................76
  - Treatment ..................................................76

**Skeletal Tuberculosis** ....................................76
  - Diagnosis ..................................................76
  - Treatment ..................................................76

**Genitourinary Tuberculosis** .............................76
  - Diagnosis ..................................................76
  - Treatment ..................................................76

**Gastrointestinal Tuberculosis** ..........................77
  - Diagnosis ..................................................77
  - Treatment ..................................................77

**Peritoneal Tuberculosis** ..................................77
  - Diagnosis ..................................................77
  - Treatment ..................................................77

**Cutaneous Tuberculosis** ..................................77
  - Diagnosis ..................................................78
  - Treatment ..................................................78

**Disease Due to Intravesical Bacille Calmette-Guérin for Bladder Cancer** ..........................78
  - Diagnosis ..................................................78
  - Treatment ..................................................78

**Suggested Regimens for Specific Drug Resistance Patterns** ......................................85
  - Isoniazid resistance ....................................87
    (with or without streptomycin resistance)
  - Isoniazid and ethambutol resistance ..........87
    (with or without streptomycin resistance)
  - Rifampin resistance .....................................87
    (with or without streptomycin resistance)
  - Isoniazid and rifampin resistance .............88
    (with or without streptomycin resistance)
  - Isoniazid, rifampin and ethambutol resistance 89
    (with or without streptomycin resistance)
  - Isoniazid, rifampin and pyrazinamide resistance 89
    (with or without streptomycin resistance)
  - Isoniazid, rifampin, pyrazinamide and ethambutol resistance 90
    (with or without streptomycin resistance)
  - Isoniazid, rifampin, ethambutol, streptomycin, kanamycin, ethionamide and rifabutin resistance ("Strain W") 90
  - Isoniazid, rifampin, ethambutol, streptomycin, fluoroquinolone resistance (with or without pyrazinamide or several injectable agents) 91

**Use of Newer Fluoroquinolones for Treating Tuberculosis** ........................................91

**Toxicities of Fluoroquinolones** ..........................92
  - Photosensitivity and cardiotoxicity ............92
  - Tendinopathy/tendonitis .............................92
  - Hypoglycemia and hyperglycemia ..................93
  - Long-term use of fluoroquinolones .............93
  - Moxifloxacin ..............................................93

**Linezolid** ..................................................94

**Clofazamine** ................................................95

**Monitoring and Post-Treatment Evaluation** ...........95

**Surgery for Pulmonary Tuberculosis** ....................95
# Table of Contents

Sputum AFB smear-negative patients known or likely to have drug-susceptible tuberculosis .....................................................127

Patients known or likely to have multidrug-resistant tuberculosis ..........129

**Home Isolation**.......................................................129

**Infection Control Issues in Pregnancy and the Peripartum Period** .......................130

Pregnant women with latent tuberculosis infection.............................................130

**Infection Control in Chest Centers** .....................131

Triage ..............................................................131

Temporary isolation .................................................131

Masks and particulate respirators ............131

**Sputum Induction** ..................................................132

Staff involved in sputum induction...........132

Equipment ........................................................132

Preparing equipment and the sputum induction room..........................132

Preparing the patient...........................................133

Role of chest center staff during the induction procedure ......................133

Handling of the specimen........................................133

Care of equipment and area between uses ........................................133

Care of room and nebulizer at the end of the day ....................................134

Documentation.......................................................134

**Key Sources** ...........................................................135

---

**Section VIII.**

Case Management of Suspected Cases and Patients with Tuberculosis in the Field and Clinic

**Initial Case Management**.............................................139

Objectives of case management.................139

---

The initial interview.................................................139

**Ensuring Effective Case Management** .........................139

Case manager initial interview topics ......141

**Ensuring Adherence** .............................................142

Common problems with, and early indicators of, poor adherence .................142

**Return-to-Supervision Activities** .................143

Follow-up for patients with tuberculosis who have missed visits and for suspected cases not on directly observed therapy......143

Follow-up on missed directly observed therapy visits..........................143

Prioritizing patients for further return to supervision .........................143

**Cohort Review** .......................................................143

Prioritization for locating nonadherent patients....................................144

Nonadherent patients who should be referred for detention.....................145

**Regulatory Intervention Options** .........................145

Commissioner’s orders ...........................................145

Tuberculosis-related regulatory interventions sections of the current Health Code.....................................................147

Procedures for infectious or potentially infectious patients who want to leave the hospital.................148

**Key Sources** ...........................................................149

---

**Section IX.**

Contact Evaluation and Public Health Management

**Importance of Contact Evaluation** .....................................153

Definitions..........................................................153

Confidentiality.....................................................155
# Table of Contents

**Epidemiological Assessment of Transmission** ...................................................... 155

**Priorities for Contact Investigation** ................................................................. 155

**Calculating the Infectious Period** .............................................................. 161

**Assessing Risk of Transmission** ................................................................. 161

**Evaluation and Management of Contacts** ............................................. 161
  - Symptom review .......................................................... 161
  - HIV screening and testing ........................................... 162
  - Initial test for tuberculosis infection and follow-up .......... 162
  - Medical evaluation and chest radiograph ....................... 163
  - Repeat test for tuberculosis infection and follow-up ...... 163
  - Contact evaluation for patients whose cultures convert back to positive ...... 164

**Special Considerations for Infant and Child Contacts** ................................ 164
  - Initial test for tuberculosis infection and chest X-ray for infants and children... 164
  - Repeat test for tuberculosis infection and chest X-ray for infants and children... 165

**Contact Investigation for Smear-Negative, Culture-Pending Cases** .............. 165

**Expanding a Contact Investigation** ................................................................. 165

**Airline Exposures** .......................................................................................... 167

**Source Case Investigation for Pediatric Tuberculosis Cases** ......................... 167

**Case Management and Treatment of Contacts with Latent Tuberculosis Infection** 169
  - Responsibilities of the case manager ....... 169
  - Return to supervision procedures for contacts being treated for latent tuberculosis infection................................. 169

**Key Sources** ...................................................................................................... 170

---

**Section X. Testing for Latent Tuberculosis Infection**

**Candidates for Testing for Latent Tuberculosis Infection** .......................... 173
  - Priorities for testing .......................................................... 173
  - Testing pregnant women .................................................. 176
  - Guidelines for testing specific high-risk groups .................. 176

**Administering the Tuberculin Skin Test** ....................................................... 178
  - Preparation ................................................................. 178
  - Injection ........................................................................ 178
  - Post-injection ................................................................ 178

**Reading the Tuberculin Skin Test Reaction** ..................................................... 179

**Interpretation of the Tuberculin Skin Test Reaction** ...................................... 179

**Interpretation of the Tuberculin Skin Test in Bacille Calmette-Guérin-Vaccinated Individuals** ......................................................... 179

**Role of Anergy Testing** .................................................................................. 182

**Two-Step Tuberculin Skin Testing** ................................................................. 182
  - Background ................................................................. 182
  - Candidates and procedure for 2-step testing ..................... 183

**Blood-Based Tests for Tuberculosis Infection: The QuantiFERON®-Gold Test** 183
  - Advantages of the QFT-G test ......................................... 183
  - Limitations of the QFT-G test ........................................ 184
  - Eligibility and interpretation of the results of the QFT-G test ...... 184
  - Costs and benefits of the QFT-G test .............................. 184

**Key Sources** ...................................................................................................... 185
# Section XI.
Latent Tuberculosis Infection: Evaluation, Treatment, Monitoring and Follow-up

## Clinical Evaluation

- Medical history and physical examination ........................................ 189
- Chest X-ray ............................................................... 189
- Patient chest X-ray classifications .............................................. 189
- Laboratory tests for individuals being considered for latent tuberculosis infection treatment ........................................... 189

## Candidates for Treatment for Latent Tuberculosis Infection

- Individuals who may have been recently infected ........................................ 192
- Patients with clinical conditions associated with progression from latent tuberculosis to active tuberculosis .............................................. 192
- Persons with immunosuppressive conditions or who are being treated with immunosuppressive agents .............................................. 192
- Contacts who should start treatment regardless of tuberculin skin test reaction .............................................. 193
- Pregnant women as candidates for latent tuberculosis infection treatment .............................................................................. 193
- Children as candidates for latent tuberculosis infection treatment .............................................. 192

## Latent Tuberculosis Infection Treatment Regimens

- Standard regimen: isoniazid ....................................................... 195
- Alternative regimen: rifampin ..................................................... 195
- Rifampin and pyrazinamide ....................................................... 198
- Alternative regimens for contacts of persons with isoniazid- and rifampin-resistant tuberculosis (multidrug-resistant contacts) .............................................. 198

Regimens for women who become pregnant while taking treatment for latent tuberculosis infection .............................................. 200
Regimens for individuals with radiographic evidence of old, healed tuberculosis (Classes IV and V) .............................................. 200
Treatment of close contacts with a prior positive test for tuberculosis infection .............................................. 202

## Case Management of Patients with Latent Tuberculosis Infection

- How providers can assess and promote adherence .............................................. 203

## Ensuring Adherence During Treatment

- Managing Interruptions in Treatment .............................................. 203

## Completing Treatment

- Follow-up for Patients Who Have Completed Treatment .............................................. 205

## Key Sources

- Appendices
  - Appendix I-A: Dosages for Primary Medications Used in the Treatment of Tuberculosis .............................................. 208
  - Appendix I-B: Dosages for Reserve Medications Used in the Treatment of Tuberculosis .............................................. 210
  - Appendix I-C: The Use of Antituberculosis Drugs During Pregnancy, Breastfeeding, Tuberculosis Meningitis, and Renal and Hepatic Failure .............................................. 211
  - Appendix I-D: Late Complications of Treated Pulmonary Tuberculosis .............................................. 212